BioSpark聊biotech news：2024年五月生物医药大事讨论 | 药时代直播间

文章预览

立即预约直播 汇聚群英智慧，闪亮你我星光 Together, Spark Biomedicine! 各领域专家汇聚在BioSpark Monthly News论坛，交流过去一个月发生的 生物医药领域大事件 。 本月热点 TOPICS 1.    2024 ASCO updates and beyond 2 .   Oncology: DLL3/CD3 BITE approval for the extensive-stage SCLC; Summit/Akeso’s PD-1/VEGF Ivonescimab vs. Keytruda in Phase 3 1L NSCLC; Arvinas’ ER degrader vepdegestrant plus Pfizer’s palbociclib in breast cancer; 3 .   Autoimmune   Diseases : J acquired Proteologix for $850M  and paid Numab $1.25B for atopic dermatitis; Biogen to acquire HI-Bio for $1.8B; GSK’s anti-IL-5 depemokimab succeeded in phase 3 severe asthma;   4 .   Other Diseases & New Modalities: Merck to acquire EyeBio for its unique Norrik mimic program; Novo Nordisk’s Factor VIII mimetic bispecific antibody in phase 3 hemophilia A; News on JNJ neuroscience spinout Rapport; Positive clinic data from Dyne for myotonic dystrophy and Duche ………………………………